METHODS: We sampled 4,902 men from the Shared Equal Access Regional Cancer Hospital (SEARCH) database treated with radical prostatectomy for non-metastatic PC at 8 Veterans Affairs hospitals between 2000 and 2017. LE was calculated using age and Charlson comorbidity index scores. Stratified linear regression was used to calculate trends in proportion of men treated with RP by D'Amico tumor risk and LE (!10 vs. <10 years) subgroups.
INTRODUCTION AND OBJECTIVES:
In ASURE technique, we preserve periprostatic fascial structures like pubovesical (PVL) ligament, anterior detrusor apron (DA) along with endopelvic fascia (EPF) to maximal extent possible and reconstruct attachment of bladder to retzius space. In essence, we try to replicate Retzius spare technique with combined posterior-anterior approach. The preservation of structures could be unilateral or bilateral, depending on merit of tumor on a particular side. This technique is being used in a customised manner depending on 1) Clinical T stage of tumor and 2) Presence of tumor close to capsular surface, NVB or apical/ anterior regions. We hypothesized that this provides earlier return to continence after RARP.
METHODS: All patients who underwent RARP by the same surgeon between May 2016 e April 2018 with at least 3 months of follow up were included . Patients were divided into three groups 1) Bilateral ASURE, 2) Unilateral ASURE, 3) Standard technique. We consider nerve to be preserved if we are able to perform intra-fascial or standard nerve spare on at least one side. Baseline and operative characteristics were noted. Primary Outcomes: early (<1 month) social continence (1 pad/24 hrs or safety liner), social continence at 1 and 3 months. Secondary outcomes: margin status, PSA at 1 month and 3 months. RESULTS: Total of 103 patients were included in the study. Group 1 (Bilateral ASURE), Group 2 (Unilateral ASURE) and Group 3(Standard bilateral) had 30, 36 and 37 patients each respectively. Baseline characteristics were similar for age, BMI, Gleason score and PSA. Group 3 had higher number of T3 patients (57%) as compared to other two groups (27%, Group 1 and 33% group 2). Nerve preservation was performed in 93%, 58% and 49% respectively in groups 1, 2 and 3. Early continence (<1 month) was seen in 7%, 5% and 3% of the patients in Groups 1, 2 and 3 respectively. One and 3 month continence outcomes for three groups were 40%, 38%, 35% and 93%,86% and 62% respectively and margin positivity rates 20%, 19% and 19% respectively. PSA at 1 month (0.01,0.06,0.07) and 3 months (0.09,0.04 and 0.08) was comparable.
CONCLUSIONS: Better continence outcomes were achieved with ASURE technique as compared to standard technique, without compromising oncologic outcomes. Bilateral ASURE was found to be better than unilateral. Unilateral ASURE achieved comparable continence outcomes to bilateral ASURE at 3 months, This supports the hypothesis that anterior support reconstruction technique can help achieve earlier continence Source of Funding: none
MP54-16 HIGHER FREE TESTOSTERONE PROTECTS AGAINST EARLY RECURRENCE IN MEN UNDERGOING RADICAL PROSTATECTOMY
Maxwell Towe, Linda M Huynh, Farouk M El-Khatib, Faysal A Yafi, Thomas Ahlering*, Orange, CA INTRODUCTION AND OBJECTIVES: The role of testosterone on prostate growth and its relationship with prostate cancer development is a controversial topic. Most current data claim that low levels of testosterone may be a risk factor for higher grade cancer. The present study seeks to assess the role of total (TT) and free testosterone (FT) in disease progression post-radical prostatectomy.
METHODS: From December 2009 to June 2018, 800 patients underwent robot-assisted radical prostatectomy (RARP) for primary treatment of localized prostate cancer by a single surgeon. Preoperative and 3 month post-operative TT and FT were prospectively collected and calculated, along with prostate specific antigen (PSA), pathological stage, and pathological grade. CONCLUSIONS: The prevalence of lymphedema after ePLND during radical prostatectomy (20.8 %) is much higher than previously reported. Lymphedema is associated with important effects on the physical and emotional well-being of patients. We confirm adjuvant radiotherapy as a risk factor for the development of lymphedema, whereas age, BMI and symptomatic lymphoceles were not withheld.
Source of Funding: None

MP54-18
INTRODUCTION AND OBJECTIVES: Lymph node dissection (LND) during radical prostatectomy (RP) for prostate cancer (PCa) aims to provide information for staging and prognosis, while oncological and survival benefits are debatable. The potential harms of LND should be balanced with the benefits on an individual risk assessment.
Given that the eligibility to an eLND is based on the prediction of an aggressive nodal disease, we aimed to explore the actual 5-and 10-years cancer specific survival (CSS) benefit of a LND with the removal of more than 11 nodes on patients with adverse pathological findings (APF) at RP.
METHODS: From the Pathological Registry of Modena (Italy), data on ORP with LND performed since 2000 were retrospectively assessed. Patients with at least 5-and 10-years follow up were considered (1,274 and 581 patients, respectively). APF at RP were recorded as follows: !pT3a in 27.9% and a GS ! 7 in 53.0%. Nodal invasion was evident in 6.4%(n[82), and positive surgical margins in 35. 4% (n[451) . The median node yield was similar among organ confined and locally advanced disease (p[0.798) and among GS[ 6 and GS! 7(p[0.392) .
Consistent with previous Literature, we divided the number of nodes removed according to a cut-off point of 11 [ 10 versus !11 (More Extended[ME-LND)]: the correlation between 5-and 10-years CSS and a ME-LND is considered as the primary outcome. Since little is known about the effects of an extended procedure in a pN0 population, the impact of ME-LND on CSS of pN0 with APF at RP is the secondary endpoint.
RESULTS: A ME-LND template was not related to 5-and 10-years CSS in the whole series and in the subgroup with nodal disease (p[ 0.33). Overall, considering pN0 PCa, a 5-years (SHR
